• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by CONMED Corporation (Amendment)

    2/13/24 5:02:29 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CNMD alert in real time by email
    SC 13G/A 1 tv0669-conmedcorp.htm SCHEDULE 13G/A conmedcorp

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 13)*

    Name of issuer:  CONMED Corp

    Title of Class of Securities:  Common Stock

    CUSIP Number:  207410101

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  207410101

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    56,625

    7.  SOLE DISPOSITIVE POWER

    3,330,420

    8.  SHARED DISPOSITIVE POWER

    89,591

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,420,011

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    11.12%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    CONMED Corp

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    11311 Concept Boulevard
    Largo, FL 33773

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    207410101

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $CNMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CNMD

    DatePrice TargetRatingAnalyst
    4/28/2025$55.00Buy → Hold
    Stifel
    2/6/2025$85.00 → $70.00Overweight → Neutral
    Analyst
    2/1/2024$119.00 → $129.00Buy
    Needham
    5/22/2023$140.00Buy
    CL King
    3/27/2023$124.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/21/2023$96.00Equal Weight
    Wells Fargo
    10/12/2022$85.00Hold
    Jefferies
    3/2/2022$155.00Neutral
    BofA Securities
    More analyst ratings

    $CNMD
    Leadership Updates

    Live Leadership Updates

    See more
    • CONMED Corporation Appoints LaVerne Council as Chair of the Board of Directors

      CONMED Corporation (NYSE:CNMD) today announced that LaVerne Council has been appointed to succeed Martha Goldberg Aronson as the new Independent Chair of its Board of Directors, effective May 21, 2025. "LaVerne's extensive experience as a global operations and information technology executive have been invaluable to CONMED, and I know that her experience will continue to serve the Board and the Company well in her new role as Chair of the Board," said Pat Beyer, President and Chief Executive Officer, CONMED. "I also want to thank Martha for her ongoing contributions to CONMED. Martha's strategic direction and steady leadership have been crucial to CONMED in her role as Chair, and her conti

      5/21/25 7:03:00 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Beta Bionics Announces the Appointment of Martha Goldberg Aronson as Chair of Its Board of Directors

      CONCORD, Mass.--(BUSINESS WIRE)--Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet® bionic pancreas system, today announced the appointment of Martha Goldberg Aronson as Chair of its Board of Directors, effective immediately. Ms. Aronson, who joined the Beta Bionics Board as a Director in February of 2020, succeeds Ed Damiano, President and Chief Executive Officer of Beta Bionics, who has served as Chair since inception of the company in 2015. Dr. Damiano will remain a member of the Board while continuing to serve in his roles as President and Chief Executive Officer of Beta Bionics. “On behalf of the Board, I am

      2/9/21 4:01:00 PM ET
      $CSII
      $MEI
      $CNMD
      Medical/Dental Instruments
      Health Care
      Electrical Products
      Technology

    $CNMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CONMED downgraded by Stifel with a new price target

      Stifel downgraded CONMED from Buy to Hold and set a new price target of $55.00

      4/28/25 8:32:52 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED downgraded by Analyst with a new price target

      Analyst downgraded CONMED from Overweight to Neutral and set a new price target of $70.00 from $85.00 previously

      2/6/25 7:05:01 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Needham reiterated coverage on CONMED with a new price target

      Needham reiterated coverage of CONMED with a rating of Buy and set a new price target of $129.00 from $119.00 previously

      2/1/24 8:15:04 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CNMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CNMD
    SEC Filings

    See more

    $CNMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Bronson David M bought $97,322 worth of shares (1,350 units at $72.09), increasing direct ownership by 9% to 16,460 units (SEC Form 4)

      4 - CONMED Corp (0000816956) (Issuer)

      5/14/24 3:37:54 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Schwarzentraub Barbara J bought $99,873 worth of shares (1,442 units at $69.26) (SEC Form 4)

      4 - CONMED Corp (0000816956) (Issuer)

      5/10/24 5:29:04 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Aronson Martha Goldberg bought $141,960 worth of shares (2,000 units at $70.98) (SEC Form 4)

      4 - CONMED Corp (0000816956) (Issuer)

      5/8/24 4:20:48 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - CONMED Corp (0000816956) (Filer)

      5/21/25 4:03:57 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form S-8 POS filed by CONMED Corporation

      S-8 POS - CONMED Corp (0000816956) (Filer)

      5/20/25 5:13:56 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form S-8 POS filed by CONMED Corporation

      S-8 POS - CONMED Corp (0000816956) (Filer)

      5/20/25 5:12:35 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Workman John L exercised 479 shares at a strike of $59.84, increasing direct ownership by 2% to 20,891 units (SEC Form 4)

      4 - CONMED Corp (0000816956) (Issuer)

      5/21/25 4:25:37 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by VP GM International Epinette Stephan

      4 - CONMED Corp (0000816956) (Issuer)

      5/15/25 9:59:45 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • New insider Epinette Stephan claimed ownership of 15,510 shares (SEC Form 3)

      3 - CONMED Corp (0000816956) (Issuer)

      5/15/25 9:57:36 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CNMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by CONMED Corporation

      SC 13G/A - CONMED Corp (0000816956) (Subject)

      11/13/24 4:22:22 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CONMED Corporation

      SC 13G/A - CONMED Corp (0000816956) (Subject)

      11/12/24 12:53:28 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by CONMED Corporation (Amendment)

      SC 13G/A - CONMED Corp (0000816956) (Subject)

      2/13/24 5:02:29 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CNMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CONMED Corporation Appoints LaVerne Council as Chair of the Board of Directors

      CONMED Corporation (NYSE:CNMD) today announced that LaVerne Council has been appointed to succeed Martha Goldberg Aronson as the new Independent Chair of its Board of Directors, effective May 21, 2025. "LaVerne's extensive experience as a global operations and information technology executive have been invaluable to CONMED, and I know that her experience will continue to serve the Board and the Company well in her new role as Chair of the Board," said Pat Beyer, President and Chief Executive Officer, CONMED. "I also want to thank Martha for her ongoing contributions to CONMED. Martha's strategic direction and steady leadership have been crucial to CONMED in her role as Chair, and her conti

      5/21/25 7:03:00 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED Corporation Announces Quarterly Cash Dividend

      CONMED Corporation (NYSE:CNMD) today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on May 20, 2025, payable on July 3, 2025, to all shareholders of record as of June 13, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release may contain forward-looking statements based on certain as

      5/21/25 7:00:00 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED Corporation Announces First Quarter 2025 Financial Results

      CONMED Corporation (NYSE:CNMD) today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales of $321.3 million increased 2.9% year-over-year as reported and 3.8% in constant currency. Domestic revenue increased 4.2% year-over-year. International revenue increased 1.2% year-over-year as reported and 3.4% in constant currency. Diluted net earnings per share (GAAP) were $0.19, compared to diluted net earnings per share (GAAP) of $0.63 in the first quarter of 2024. Adjusted diluted net earnings per share(1) were $0.95, compared to adjusted diluted net earnings per share of $0.79 in the first quarter of 2024. "We had a good start t

      4/30/25 4:05:00 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CNMD
    Financials

    Live finance-specific insights

    See more
    • CONMED Corporation Announces Quarterly Cash Dividend

      CONMED Corporation (NYSE:CNMD) today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on May 20, 2025, payable on July 3, 2025, to all shareholders of record as of June 13, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release may contain forward-looking statements based on certain as

      5/21/25 7:00:00 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED Corporation Announces First Quarter 2025 Financial Results

      CONMED Corporation (NYSE:CNMD) today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales of $321.3 million increased 2.9% year-over-year as reported and 3.8% in constant currency. Domestic revenue increased 4.2% year-over-year. International revenue increased 1.2% year-over-year as reported and 3.4% in constant currency. Diluted net earnings per share (GAAP) were $0.19, compared to diluted net earnings per share (GAAP) of $0.63 in the first quarter of 2024. Adjusted diluted net earnings per share(1) were $0.95, compared to adjusted diluted net earnings per share of $0.79 in the first quarter of 2024. "We had a good start t

      4/30/25 4:05:00 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED Corporation to Announce First Quarter 2025 Financial Results on April 30, 2025

      CONMED Corporation (NYSE:CNMD) today announced that it will report financial results for the first quarter 2025 after the market close on Wednesday, April 30, 2025. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a medical t

      4/2/25 4:05:00 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care